Dr. Steven Shak on the Results of the TAILORx Trial for Breast Cancer

Shak says the study examined the prospective outcomes of 1626 women and showed that at 5 years, less than 1% of women had a distant recurrence.

Steven Shak, MD, chief Scientific Officer, Oncotype Dx, discusses the good news for patients with breast cancer emerging from the NCI-sponsored Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, trial.

The goal of the trial was to examine the effects of chemotherapy in patients with breast cancer who had a midrange recurrent score from 12 to 25. The analysis includes additional single gene results from patients with recurrence scores less than 11 who received hormonal therapy alone.